Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The advent of Alzheimer treatments will change the trajectory of human aging
Dennis J. Selkoe
Nature Aging (2024) Vol. 4, Iss. 4, pp. 453-463
Closed Access | Times Cited: 13

Showing 13 citing articles:

The immunology of stroke and dementia
Costantino Iadecola, Josef Anrather
Immunity (2025) Vol. 58, Iss. 1, pp. 18-39
Closed Access
Should the preclinical stage of Alzheimer's disease be disclosed?
Colin L. Masters
The Lancet Neurology (2025) Vol. 24, Iss. 2, pp. 94-95
Closed Access
Communicating scientific evidence: drugs for Alzheimer's disease as a case study
Kasper P. Kepp, Poul F. Høilund‐Carlsen, Ioana A. Cristea, et al.
Current Medical Research and Opinion (2025), pp. 1-15
Closed Access
Quantification of amyloid-β aggregation inhibitors gallic acid and rosmarinic acid in biological samples by LC-MS/MS
Raluca Ştefănescu
Analytical Biochemistry (2025), pp. 115799-115799
Open Access
Chiral Inorganic Nanomaterial‐Based Diagnosis and Treatments for Neurodegenerative Diseases
Jingqi Dong, Liguang Xu, Aihua Qu, et al.
Advanced Materials (2025)
Closed Access
HCN2 deficiency correlates with memory deficits and hyperexcitability of dCA1 pyramidal neurons in Alzheimer’s disease
Xiaoqin Zhang, Yiping Zhang, Ting Zhang, et al.
Alzheimer s Research & Therapy (2025) Vol. 17, Iss. 1
Open Access
Maximizing the benefit and managing the risk of anti-amyloid monoclonal antibody therapy for Alzheimer's disease: Strategies and research directions
Jeffrey L. Cummings
Neurotherapeutics (2025), pp. e00570-e00570
Open Access
In 2024, the amyloid-cascade-hypothesis still remains a working hypothesis, no less but certainly no more
Christian Behl
Frontiers in Aging Neuroscience (2024) Vol. 16
Open Access | Times Cited: 2
The Amyloid Cascade Hypothesis: A Conclusion in Search of Support
Rudolph J. Castellani, Pouya Jamshidi, Germán Plascencia‐Villa, et al.
American Journal Of Pathology (2024)
Closed Access | Times Cited: 2
Multimodal Hyperbolic Graph Learning for Alzheimer's Disease Detection
C. Xie, Wenhao Zhou, Ciyuan Peng, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Multimodal Hyperbolic Graph Learning for Alzheimer’s Disease Detection
C. Xie, Wenhao Zhou, Ciyuan Peng, et al.
Lecture notes in computer science (2024), pp. 390-403
Closed Access
Aβ-Amyloid Lowering with Monoclonal Antibodies for Alzheimer's Disease: Appropriate Use Recommendations for Australasian Conditions
Colin L. Masters, Lavier Gomes, Nicholas H. G. Holford, et al.
SSRN Electronic Journal (2024)
Closed Access
The case for regulatory approval of amyloid‐lowering immunotherapies in Alzheimer's disease based on clearcut biomarker evidence
Paul Aisen, Randall J. Bateman, Damian C. Crowther, et al.
Alzheimer s & Dementia (2024)
Open Access
Page 1

Scroll to top